.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,845,075

« Back to Dashboard

Claims for Patent: 4,845,075

Title: Biologically active B-chain homodimers
Abstract:Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s): Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Application Number:06/942,161
Patent Claims: 1. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 109.

2. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 109.

3. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 15 to amino acid 101.

4. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 29 to amino acid 101.

5. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 101.

6. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of the B-chain of PDGF from amino acid 1 to amino acid 109.

7. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 15 to amino acid 109.

8. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 29 to amino acid 109.

9. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 15 to amino acid 101.

10. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 29 to amino acid 101.

11. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 1 to amino acid 101.

12. An isolated protein having two polypeptide chains, each of said chains comprising the amino acid sequence of p28-sis corresponding to the B-chain of PDGF from amino acid 1 to amino acid 109.

13. A wound-healing composition comprising a therapeutically effective amount of an isolated protein according to any one of claims 1-12, and a physiologically acceptable carrier or diluent.

14. The wound-healing composition of claim 13 wherein the carrier or diluent is selected from the group consisting of albumin, saline and sterile water.

15. The wound-healing composition of claim 13, including an adjuvant.

16. The wound-healing composition of claim 15 wherein the adjuvant is selected from the group consisting of collagen, hyaluronic acid preparations, fibronectin and factor XIII.

17. A method for enhancing the wound healing process in a warm-blooded animal, comprising administering to the animal a composition according to any one of claims 13-16.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc